Yongqian Shu
机构：Qinghai University, Xinjiang Medical University, Guizhou University, Chinese Academy of Sciences, China National Salt Industry Corporation (China), Tumor Hospital of Xinjiang Medical University, Jiangsu Cancer Hospital, Jiangsu Province Hospital, University of Chinese Academy of Sciences, Qinghai Institute of Salt Lakes, Nanjing Medical University · ORCID：0000-0003-2103-0877
发表论文 315 篇 · 总被引 15014 次 · h-index 52
代表论文
- First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 71)
- HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma (2024 · Journal for ImmunoTherapy of Cancer · 被引 40)
- Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study (2024 · Journal for ImmunoTherapy of Cancer · 被引 26)
- NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial (2025 · Journal of Clinical Oncology · 被引 17)
- Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial (2025 · The Lancet Oncology · 被引 16)
- Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes (2025 · npj Precision Oncology · 被引 14)